The new product, called MeMed BV Flex, delivers results in 15 minutes and is designed for use in decentralized clinics and other point-of-care settings.
While the immediate application is diagnosing MDS and leukemia risk, researchers believe the technique could eventually be used to detect a range of blood-related disorders earlier and less invasively.